2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Other Events
Financial Results, Press Release
Lease Amendment - Senti Biosciences Reduces Leased Premises Size
Investor Presentation
Senti Bio Q3 2025 Financial Results and Next Clinical Data for SENTI-202 Study
Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Submission of Matters to a Vote of Security Holders
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence